<DOC>
	<DOCNO>NCT02682667</DOCNO>
	<brief_summary>Background : Cancer major impact United States across world . In 2015 , 1.5 million new case cancer diagnose U.S . Researchers want study sample people cancer pre-malignant condition . They hope develop effective treatment . Objective : To good understand biology malignancy certain cancer respond differently treatment . Eligibility : Adults least 18 year old cancer pre-cancerous condition . Design : Participants screen medical history , physical exam , blood test . Their diagnosis confirm NCI Laboratory Pathology . Participants send tissue block slide original tumor biopsy . At least , participant medical history , physical exam , blood urine test . Participants may follow test . They may : Apheresis . A needle one arm remove blood . Blood run machine sample cell take . The rest blood return needle arm . Bone marrow aspiration biopsy . The hipbone numbed . A needle put hipbone . Bone marrow take needle . Piece cancer tissue take needle syringe . Computed tomography ( CT ) scan , magnetic resonance imaging ( MRI ) and/or positron emission tomography ( PET ) scan ultrasound help locate tumor . For scan , lie machine take picture . A small piece skin remove . Participants contact phone year find .</brief_summary>
	<brief_title>Biospecimen Procurement Experimental Transplantation Immunology Branch Immunotherapy Protocols</brief_title>
	<detailed_description>Background : -Immunotherapy promise approach treatment cancer . ETIB investigator study immunotherapy treatment diverse malignant premalignant condition . These study require collection biospecimens research purpose . Objectives : - To collect bank blood , apheresis product , tumor , body fluid , biospecimens patient cancer premalignant disease . - To collect bank biospecimens direct companion ETIB immunotherapy clinical trial protocol . - To conduct nucleic acid , protein , immunological biological research study sample collect . Eligibility : -Patients must 18 year age old diagnosis cancer premalignant condition . Design : - Up 500 subject enrol . - Patients undergo sample blood , apheresis product , tumor , effusion , ascites , urine , bone marrow , serum , plasma , skin , mucosa , tissue bank laboratory study . - No investigational experimental therapy give part protocol .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosis cancer premalignant condition 2 . Age great equal 18 year age 3 . ECOG performance status 03 4 . Ability willingness subject provide inform consent INCLUSION FOR APHERESIS : 1 . Hemoglobin great equal 8 mg/dL platelet count &gt; 75 K/uLuL 2 . Weight great equal 48 kg 3 . Central line place adequate venous access . EXCLUSION CRITERIA : 1 . Active concomitant medical psychological illness may increase risk subject . 2 . Inability obtain informed consent 3 . Allogenic stem cell transplant recipient due inability obtain informed consent stem cell donor . 4 . Pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 28, 2017</verification_date>
	<keyword>Apheresis Products</keyword>
	<keyword>Immunological</keyword>
	<keyword>Diverse Malignan</keyword>
	<keyword>Premalignant</keyword>
	<keyword>Protein</keyword>
</DOC>